Parkinson Disease (PD) Clinical Trial
Official title:
Canadian Advanced Parkinson DUODOPA-Treated Patients Observational Study Evaluating Long-Term Health Outcomes in Centers of Excellence (CADENCE)
| NCT number | NCT02485600 |
| Other study ID # | P14-506 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | October 19, 2015 |
| Est. completion date | February 26, 2020 |
| Verified date | June 2021 |
| Source | AbbVie |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson's disease and long-term treatment with Duodopa (levodopa/carbidopa intestinal gel).
| Status | Completed |
| Enrollment | 88 |
| Est. completion date | February 26, 2020 |
| Est. primary completion date | February 26, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 99 Years |
| Eligibility | Inclusion Criteria: - Diagnosed with advanced Parkinson's Disease - Prescribed Duodopa by his/her treating physician. Exclusion Criteria: - Patients who were previously treated with Duodopa. - Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of advanced PD. |
| Country | Name | City | State |
|---|---|---|---|
| Canada | University of Calgary /ID# 151948 | Calgary | Alberta |
| Canada | Zeidler Ledcor Centre /ID# 135979 | Edmonton | Alberta |
| Canada | Hamilton Health Sciences /ID# 148808 | Hamilton | Ontario |
| Canada | Kingston General Hospital /ID# 144942 | Kingston | Ontario |
| Canada | London Health Sciences Centre /ID# 138434 | London | Ontario |
| Canada | McGill Univ HC /ID# 138334 | Montreal | Quebec |
| Canada | CHUM - Notre-Dame Hospital /ID# 135977 | Montréal | Quebec |
| Canada | The Ottawa Hospital /ID# 135981 | Ottawa | Ontario |
| Canada | CSSS Alphonse-Desjardins, CHAU de Levis /ID# 144941 | Quebec City | Quebec |
| Canada | Ctr Hosp Enfant Jesus /ID# 138435 | Quebec City | Quebec |
| Canada | CHUS - Hopital Fleurimont /ID# 148811 | Sherbrooke | Quebec |
| Canada | Toronto Western Hospital /ID# 135980 | Toronto | Ontario |
| Canada | St. Boniface Clinic, CA /ID# 162092 | Winnipeg | Manitoba |
| Lead Sponsor | Collaborator |
|---|---|
| AbbVie |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in participant's motor symptoms | Evaluated via the Unified Parkinson's Disease Rating Scale (UPDRS) Part II, III, V and Part IV items 33-35; items 32 & 39 modified as per MDS-UPDRS, and the Freezing of Gait Questionnaire (FOGQ). | Baseline, Day 1, Month 3, Month 6, and every 6 months thereafter up to 48 months | |
| Primary | Change in the cognitive functions. | Evaluated via the Montreal Cognitive Assessment (MoCa). | Baseline, Day 1, and every 12 months thereafter up to 48 months | |
| Primary | Change in the Parkinson's Disease Questionnaire (PDQ-39) | Evaluated via the Parkinson's Disease Questionnaire (PDQ-39) | Baseline, Day 1, Month 3, and every 6 months thereafter up to 48 months | |
| Primary | Change in caregiver burden | Evaluated via the Zarit Care Giver Burden Questionnaire. | Baseline, Day 1, Month 3, and every 6 months thereafter up to 48 months | |
| Primary | Change in the non-motor symptoms. | Evaluated via the Non-Motor symptoms Scale (NMS) and the Parkinson's Disease Sleep Scale (PDSS-2). | Baseline, Day 1, Month 3, and very 6 months thereafter up to 48 months | |
| Primary | Change in caregiver work productivity | Evaluated by the Work Productivity and Activity Information Questionnaire (WPAI - care giver) | Baseline, Day 1, Month 3, and every 6 months thereafter up to 48 months | |
| Primary | Change in the participant's Healthcare Resource Utilization | Evaluated via the Health Care Resources Utilization Questionnaire (HCRU). | Baseline, Month 3, and every 6 months thereafter up to 48 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03840252 -
Progression of Striatal and Extrastriatal Degeneration in PD and PSP Patients
|
N/A | |
| Withdrawn |
NCT05033912 -
A Study of CST-2032 in Subjects With Cognitive Impairment
|
Phase 1 | |
| Completed |
NCT03961282 -
CODY (Co-design for You): An Immersive Technology Tool for Experiencing and Assessing Home Alterations
|
N/A | |
| Active, not recruiting |
NCT04041193 -
An Innovative Disease-net Management Model for Non-communicable Diseases (SIDERA^B)
|
N/A | |
| Recruiting |
NCT05395624 -
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
|
Phase 1/Phase 2 |